Puma Biotechnology PBYI
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 76th percentile, 5-year average 0.3x
#1346 of 2992 stocks by PE (1 = cheapest)
Below its usual level · 38th percentile, 5-year average 1.9x
#3615 of 5329 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 92nd percentile, 5-year average 0.9x
#2352 of 5156 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 2.74 | – | 1.92 | 38% (cheaper than usual) | #3615 of 5329 (1 = cheapest) |
| PE | 16.89 | 26.43 | 0.33 | 76% (pricier than usual) | #1346 of 2992 (1 = cheapest) |
| PS | 1.73 | 1.77 | 0.92 | 92% (pricier than usual) | #2352 of 5156 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on PBYI.
Sign in to join the discussion.